UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $340,000 Stock Position in Arbutus Biopharma Co. (NASDAQ:ABUS)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its position in Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 46.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 103,943 shares of the biopharmaceutical company's stock after selling 91,900 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.05% of Arbutus Biopharma worth $340,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new position in shares of Arbutus Biopharma during the 4th quarter worth approximately $34,000. Xponance Inc. bought a new stake in shares of Arbutus Biopharma during the 4th quarter valued at $34,000. E Fund Management Co. Ltd. acquired a new stake in shares of Arbutus Biopharma in the 4th quarter valued at approximately $34,000. Cibc World Markets Corp acquired a new position in shares of Arbutus Biopharma in the 4th quarter valued at $45,000. Finally, Hsbc Holdings PLC bought a new stake in shares of Arbutus Biopharma in the fourth quarter worth about $55,000. Institutional investors and hedge funds own 43.79% of the company's stock.

Arbutus Biopharma Stock Performance

Shares of ABUS traded up $0.05 during mid-day trading on Monday, reaching $3.58. The company had a trading volume of 751,939 shares, compared to its average volume of 967,307. The company's 50 day simple moving average is $3.32 and its 200 day simple moving average is $3.33. The company has a market capitalization of $685.67 million, a price-to-earnings ratio of -8.33 and a beta of 1.23. Arbutus Biopharma Co. has a 1-year low of $2.71 and a 1-year high of $4.73.

Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) last issued its earnings results on Wednesday, May 14th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.04). The company had revenue of $1.76 million during the quarter, compared to analyst estimates of $2.54 million. Arbutus Biopharma had a negative net margin of 1,137.65% and a negative return on equity of 68.18%. As a group, equities analysts forecast that Arbutus Biopharma Co. will post -0.39 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on ABUS shares. Chardan Capital reiterated a "buy" rating and issued a $5.00 price objective on shares of Arbutus Biopharma in a research report on Friday, March 28th. Wall Street Zen raised shares of Arbutus Biopharma from a "sell" rating to a "hold" rating in a research report on Saturday, March 29th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Arbutus Biopharma presently has an average rating of "Moderate Buy" and a consensus price target of $5.50.

Arbutus Biopharma Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.